ROIV Roivant Sciences
- 11.130
- -0.080-0.71%
Roivant Sciences News
Institutional Investors Are Roivant Sciences Ltd.'s (NASDAQ:ROIV) Biggest Bettors and Were Rewarded After Last Week's US$290m Market Cap Gain
Buy Rating Justified by Roivant Sciences' Strategic Positioning and Promising Drug Pipeline
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
7 analysts have expressed a variety of opinions on Roivant Sciences (NASDAQ:ROIV) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table encapsulates the
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $18.00.
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $18.00.
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price target.
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
Institutional Investors in Roivant Sciences Ltd. (NASDAQ:ROIV) Lost 7.3% Last Week but Have Reaped the Benefits of Longer-term Growth
Key Insights Significantly high institutional ownership implies Roivant Sciences' stock price is sensitive to their trading actions 52% of the business is held by the top 7 shareholders Insiders
Roivant Sciences Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since August 2022 -- Data Talk
Roivant Sciences Ltd. (ROIV) is currently at $10.58, down $0.13 or 1.17% --Would be lowest close since April 1, 2024, when it closed at $10.43 --Currently down eight consecutive days; down 9.84% ove
Unusual Options Activity: SBUX, ROIV and Others Attract Market Bets, SBUX V/OI Ratio Reaches 111.0
EST Apr 5th Closing Delivery - In the last three hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Arbutus Biopharma Jumps After Patent Victory in Fight With Moderna
Roivant Sciences Price Target Raised to $18.00/Share From $16.00 by Goldman Sachs
Roivant Sciences Price Target Raised to $18.00/Share From $16.00 by Goldman Sachs
Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18
Goldman Sachs analyst Corinne Jenkins maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $16 to $18.
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.
Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating
Roivant Sciences (ROIV) has an average rating of Buy and price targets ranging from $12 to $23, according to analysts polled by Capital IQ. Price: 11.16, Change: +0.24, Percent Change: +2.2
Buy Rating Affirmed for Roivant Sciences Amid Brepocitinib Success and Strategic Share Repurchase Program
Deutsche Bank Maintains Buy on Roivant Sciences, Raises Price Target to $15
Deutsche Bank analyst Neena Bitritto-Garg maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $14 to $15.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Inari Medical (NARI) and Roivant Sciences (ROIV)
Analysis
Price Target
No Data
